Characterization and demonstration of drug compound ring-chain tautomer formation and its impacts on quality control-Reference-Cited by-同舟云学术

Characterization and demonstration of drug compound ring-chain tautomer formation and its impacts on quality control

Published:2021-05 Issue: Volume:198 Page:114020
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Ottosson Jenny E.^ORCID,Gränfors Malin,van Pelt Sally,Langborg Weinmann Annika,Nilsson Lill Sten O.,Hulthe Gustaf,Grönberg Gunnar

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference29 articles.

1. Initial clinical experience with AZD5718, a novel once daily oral 5-Lipoxygenase activating protein inhibitor;Ericsson;Clin. Transl. Sci.,2018

2. Discovery and early clinical development of inhibitor of 5-Lipoxygenase activating protein (AZD5718) for treatment of coronary artery disease;Pettersen;J. Med. Chem.,2019

3. Novel chemical series of 5-Lipoxygenase-activating protein inhibitors for treatment of coronary artery disease;Lemurell;J. Med. Chem.,2019

4. Recent advances for FLAP inhibitors;Pettersen;Bioorg. Med. Chem. Lett.,2015

5. International Conference on Harmonization (ICH) Q6A: specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances. https://database.ich.org/sites/default/files/Q6A_Guideline.pdf, 1999 (accessed 5.11.2020).

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Importance of tautomerism in drugs;Drug Discovery Today;2023-04

2. Equilibrium types in HPLC;Essentials in Modern HPLC Separations;2022